Loading...
Market
How will Lykos Therapeutics' stock price react within 1 week after FDA decision on MDMA-assisted therapy for PTSD?
2
Resolution / Starting Odds
Increase by more than 20% • 25%
Increase by 10-20% • 25%
No significant change • 25%
Decrease • 25%
Stock market data from financial news sources
Story
FDA Rejects MDMA for PTSD Treatment, Requests More Research
Aug 9, 2024, 09:21 PM
The U.S. Food and Drug Administration (FDA) has rejected the application for the use of MDMA-assisted therapy to treat PTSD. The decision marks a setback for the psychedelic space, as the agency has requested an additional Phase 3 study to further investigate the safety and effectiveness of MDMA. Lykos Therapeutics, the company behind the application, will need to conduct further research to address the FDA's concerns.
View original story
Similar markets
Increase by 5% or more • 25%
Increase by less than 5% • 25%
Decrease • 25%
No significant change • 25%
Approved without restrictions • 25%
Approved with restrictions • 25%
Rejected • 25%
Decision delayed • 25%
Increases by more than 10% • 25%
Increases by 5-10% • 25%
Changes by less than 5% • 25%
Decreases • 25%
Approved without restrictions • 25%
Approved with restrictions • 25%
Not approved • 25%
Decision delayed • 25%
Stock price increases by over 20% • 25%
Stock price increases by 10-20% • 25%
Stock price changes by less than 10% • 25%
Stock price decreases • 25%
Stock increases by more than 10% • 25%
Stock increases by 5-10% • 25%
Stock changes by less than 5% • 25%
Stock decreases • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increase by 5% or more • 25%
Increase by less than 5% • 25%
Decrease • 25%
No significant change • 25%
Increase > 20% • 25%
Increase 10-20% • 25%
Increase < 10% • 25%
Decrease • 25%
Increase by over 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by over 10% • 25%
